Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Azopt
AZOPT 10 mg/ml eye drops, suspension · Abschnitt 4.5 · PDF-Seite 4–5
HOS-090573 · Präparat HOS-084087
4
The cytochrome P-450 isozymes responsible for metabolism of brinzolamide include CYP3A4 (main),
CYP2A6, CYP2C8 and CYP2C9. It is expected that inhibitors of CYP3A4 such as ketoconazole,
itraconazole, clotrimazole, ritonavir and troleandomycin will inhibit the metabolism of brinzolamide
by CYP3A4. Caution is advised if CYP3A4 inhibitors are given concomitantly. However,
accumulation of brinzolamide is unlikely as renal elimination is the major route. Brinzolamide is not
an inhibitor of cytochrome P-450 isozymes.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) clotrimazole (HOS-090574) itraconazole (HOS-084516) troleandomycin (HOS-090575) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-09T11:23:00Z · SHA-256 d0be850656f9509e71878bc85c7d0b4029d40e9296b4026f616ccfa56bd15b67 · Passage 1cb8578282141ccd7e7c5127a0661aba79ce86b7afac0f06741f560b1122da98 · Zeichen 693–1212 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 1 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 8
HOS-090592 · Präparat HOS-084095
Sirolimus is extensively metabolised by the CYP3A4 isozyme in the intestinal wall and liver.
Sirolimus is also a substrate for the multidrug efflux pump, P-glycoprotein (P-gp) located in the small
intestine. Therefore, absorption and the subsequent elimination of sirolimus may be influenced by
substances that affect these proteins. Inhibitors of CYP3A4 (such as ketoconazole, voriconazole,
itraconazole, telithromycin, or clarithromycin) decrease the metabolism of sirolimus and increase
sirolimus levels. Inducers of CYP3A4 (such as rifampin or rifabutin) increase the metabolism of
sirolimus and decrease sirolimus levels. Co-administration of sirolimus with strong inhibitors of
CYP3A4 or inducers of CYP3A4 is not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifampin (HOS-088791) ketoconazole (HOS-084513) rifabutin (HOS-086262) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 159852d4b6d56d956ff9fb4bd74e5bc0c13922c9c8af0ccc6125f8aa005e10e7 · Zeichen 0–750 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 1 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 10
HOS-090616 · Präparat HOS-084095
Inhibitors of CYP3A4 may decrease the metabolism of sirolimus and increase sirolimus blood levels.
Such inhibitors include certain antifungals (e.g. clotrimazole, fluconazole, itraconazole, voriconazole),
certain antibiotics (e.g. troleandomycin, telithromycin, clarithromycin), certain protease inhibitors (e.g.
ritonavir, indinavir, boceprevir, telaprevir), nicardipine, bromocriptine, cimetidine, danazol and
letermovir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) letermovir (HOS-090621) nicardipine (HOS-090619) protease (HOS-085623) cimetidine (HOS-085835) clotrimazole (HOS-090574) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) danazol (HOS-085473) fluconazole (HOS-087945) boceprevir (HOS-090617) clarithromycin (HOS-084517) troleandomycin (HOS-090575) bromocriptine (HOS-090620) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 5e78d73fd3b12aea3ede2eeac1a14a3dfb8e863d7c5ea6929177114d000b7a9c · Zeichen 5491–5914 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 0.5 mg coated tablets Rapamune 1 mg coated tablets Rapamune 2 mg coated tablets · Abschnitt 4.5 · PDF-Seite 29
HOS-090664 · Präparat HOS-084095
Sirolimus is extensively metabolised by the CYP3A4 isozyme in the intestinal wall and liver.
Sirolimus is also a substrate for the multidrug efflux pump, P-glycoprotein (P-gp) located in the small
intestine. Therefore, absorption and the subsequent elimination of sirolimus may be influenced by
substances that affect these proteins. Inhibitors of CYP3A4 (such as ketoconazole, voriconazole,
itraconazole, telithromycin, or clarithromycin) decrease the metabolism of sirolimus and increase
sirolimus levels. Inducers of CYP3A4 (such as rifampin or rifabutin) increase the metabolism of
sirolimus and decrease sirolimus levels. Co-administration of sirolimus with strong inhibitors of
CYP3A4 or inducers of CYP3A4 is not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifampin (HOS-088791) ketoconazole (HOS-084513) rifabutin (HOS-086262) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 159852d4b6d56d956ff9fb4bd74e5bc0c13922c9c8af0ccc6125f8aa005e10e7 · Zeichen 0–750 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 0.5 mg coated tablets Rapamune 1 mg coated tablets Rapamune 2 mg coated tablets · Abschnitt 4.5 · PDF-Seite 30
HOS-090685 · Präparat HOS-084095
Inhibitors of CYP3A4 may decrease the metabolism of sirolimus and increase sirolimus blood levels.
Such inhibitors include certain antifungals (e.g. clotrimazole, fluconazole, itraconazole, voriconazole),
certain antibiotics (e.g. troleandomycin, telithromycin, clarithromycin), certain protease inhibitors (e.g.
ritonavir, indinavir, boceprevir, and telaprevir), nicardipine, bromocriptine, cimetidine, danazol and
letermovir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) letermovir (HOS-090621) nicardipine (HOS-090619) protease (HOS-085623) cimetidine (HOS-085835) clotrimazole (HOS-090574) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) danazol (HOS-085473) fluconazole (HOS-087945) boceprevir (HOS-090617) clarithromycin (HOS-084517) troleandomycin (HOS-090575) bromocriptine (HOS-090620) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 238f7546225e192c0d4817ab6a1671062b9e93e1fd99e257fa0ce448f21b38a0 · Zeichen 5433–5860 im Abschnitt
Wechselwirkungen · Targretin
Targretin 75 mg soft capsules · Abschnitt 4.5 · PDF-Seite 5
HOS-091526 · Präparat HOS-084349
Effects of other substances on bexarotene
No formal studies to evaluate interactions with bexarotene have been conducted. On the basis of the
oxidative metabolism of bexarotene by cytochrome P450 3A4 (CYP3A4), coadministration with other
CYP3A4 substrates such as ketoconazole, itraconazole, protease inhibitors, clarithromycin and
erythromycin may theoretically lead to an increase in plasma bexarotene concentrations. Furthermore,
co-administration with CYP3A4 inducers such as rifampicin, phenytoin, dexamethasone or
phenobarbital may theoretically cause a reduction in plasma bexarotene concentrations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) phenobarbital (HOS-085617) ketoconazole (HOS-084513) dexamethasone (HOS-084535) lead (HOS-085592) itraconazole (HOS-084516) clarithromycin (HOS-084517) erythromycin (HOS-084514) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-12T12:14:00Z · SHA-256 3bf4d2f2fd7cbd6812f185953fbdb6223f58862715009080d9c1b2058c9f08b5 · Passage be5f9d9ff4d76d4b8473caec9b0e2e223aad8970f837bc7e78b263d876520dda · Zeichen 0–606 im Abschnitt
Wechselwirkungen · Prandin
Prandin 0.5 mg tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-108637 · Präparat HOS-093055
The following substances may enhance and/or prolong the hypoglycaemic effect of repaglinide:
Gemfibrozil, clarithromycin, itraconazole, ketokonazole, trimethoprim, ciclosporin, deferasirox,
clopidogrel, other antidiabetic substances, monoamine oxidase inhibitors (MAOI), non selective beta
blocking substances, angiotensin converting enzyme (ACE)-inhibitors, salicylates, NSAIDs,
octreotide, alcohol, and anabolic steroids.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) deferasirox (HOS-088409) octreotide (HOS-085481) gemfibrozil (HOS-088403) itraconazole (HOS-084516) clopidogrel (HOS-087927) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2018-05-14T02:00:00Z · SHA-256 4c973e31eb747a16f464340bcfe327b4eb470ef0597a3a9d0a9fc8e0d35f01d0 · Passage 30e88e7089f9852628a532c33d69941afc06407fddd7567690084ca1e89404a7 · Zeichen 1135–1558 im Abschnitt
Wechselwirkungen · Prandin
Prandin 0.5 mg tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-108642 · Präparat HOS-093055
The effect of ketoconazole, a prototype of potent and competitive inhibitors of CYP3A4, on the
pharmacokinetics of repaglinide has been studied in healthy subjects. Co-administration of 200 mg
ketoconazole increased the repaglinide (AUC and Cmax) by 1.2-fold with profiles of blood glucose
concentrations altered by less than 8% when administered concomitantly (a single dose of 4 mg
repaglinide). Co-administration of 100 mg itraconazole, an inhibitor of CYP3A4, has also been
studied in healthy volunteers, and increased the AUC by 1.4-fold. No significant effect on the glucose
level in healthy volunteers was observed. In an interaction study in healthy volunteers, co-
administration of 250 mg clarithromycin, a potent mechanism-based inhibitor of CYP3A4, slightly
increased the repaglinide (AUC) by 1.4-fold and Cmax by 1.7-fold and increased the mean incremental
AUC of serum insulin by 1.5-fold and the maximum concentration by 1.6-fold. The exact mechanism
of this interaction is not clear.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) glucose (HOS-088412) itraconazole (HOS-084516) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2018-05-14T02:00:00Z · SHA-256 4c973e31eb747a16f464340bcfe327b4eb470ef0597a3a9d0a9fc8e0d35f01d0 · Passage 87f43c80efc4087eb3a239c087cbe51c7443c8eec3071c799c234a855ad41389 · Zeichen 3892–4891 im Abschnitt
Wechselwirkungen · Prandin
Prandin 1 mg tablets · Abschnitt 4.5 · PDF-Seite 15
HOS-108672 · Präparat HOS-093055
The following substances may enhance and/or prolong the hypoglycaemic effect of repaglinide:
Gemfibrozil, clarithromycin, itraconazole, ketokonazole, trimethoprim, ciclosporin, deferasirox,
clopidogrel, other antidiabetic substances, monoamine oxidase inhibitors (MAOI), non selective beta
blocking substances, angiotensin converting enzyme (ACE)-inhibitors, salicylates, NSAIDs,
octreotide, alcohol, and anabolic steroids.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) deferasirox (HOS-088409) octreotide (HOS-085481) gemfibrozil (HOS-088403) itraconazole (HOS-084516) clopidogrel (HOS-087927) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2018-05-14T02:00:00Z · SHA-256 4c973e31eb747a16f464340bcfe327b4eb470ef0597a3a9d0a9fc8e0d35f01d0 · Passage 30e88e7089f9852628a532c33d69941afc06407fddd7567690084ca1e89404a7 · Zeichen 1136–1559 im Abschnitt
Wechselwirkungen · Prandin
Prandin 1 mg tablets · Abschnitt 4.5 · PDF-Seite 15
HOS-108677 · Präparat HOS-093055
The effect of ketoconazole, a prototype of potent and competitive inhibitors of CYP3A4, on the
pharmacokinetics of repaglinide has been studied in healthy subjects. Co-administration of 200 mg
ketoconazole increased the repaglinide (AUC and Cmax) by 1.2-fold with profiles of blood glucose
concentrations altered by less than 8% when administered concomitantly (a single dose of 4 mg
repaglinide). Co-administration of 100 mg itraconazole, an inhibitor of CYP3A4, has also been
studied in healthy volunteers, and increased the AUC by 1.4-fold. No significant effect on the glucose
level in healthy volunteers was observed. In an interaction study in healthy volunteers, co-
administration of 250 mg clarithromycin, a potent mechanism-based inhibitor of CYP3A4, slightly
increased the repaglinide (AUC) by 1.4-fold and Cmax by 1.7-fold and increased the mean incremental
AUC of serum insulin by 1.5-fold and the maximum concentration by 1.6-fold. The exact mechanism
of this interaction is not clear.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) glucose (HOS-088412) itraconazole (HOS-084516) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2018-05-14T02:00:00Z · SHA-256 4c973e31eb747a16f464340bcfe327b4eb470ef0597a3a9d0a9fc8e0d35f01d0 · Passage 87f43c80efc4087eb3a239c087cbe51c7443c8eec3071c799c234a855ad41389 · Zeichen 3893–4892 im Abschnitt
Wechselwirkungen · Prandin
Prandin 2 mg tablets · Abschnitt 4.5 · PDF-Seite 25
HOS-108707 · Präparat HOS-093055
The following substances may enhance and/or prolong the hypoglycaemic effect of repaglinide:
Gemfibrozil, clarithromycin, itraconazole, ketokonazole, trimethoprim, ciclosporin, deferasirox,
clopidogrel, other antidiabetic substances, monoamine oxidase inhibitors (MAOI), non selective beta
blocking substances, angiotensin converting enzyme (ACE)-inhibitors, salicylates, NSAIDs,
octreotide, alcohol, and anabolic steroids.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) deferasirox (HOS-088409) octreotide (HOS-085481) gemfibrozil (HOS-088403) itraconazole (HOS-084516) clopidogrel (HOS-087927) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2018-05-14T02:00:00Z · SHA-256 4c973e31eb747a16f464340bcfe327b4eb470ef0597a3a9d0a9fc8e0d35f01d0 · Passage 30e88e7089f9852628a532c33d69941afc06407fddd7567690084ca1e89404a7 · Zeichen 1136–1559 im Abschnitt
Wechselwirkungen · Prandin
Prandin 2 mg tablets · Abschnitt 4.5 · PDF-Seite 25
HOS-108712 · Präparat HOS-093055
The effect of ketoconazole, a prototype of potent and competitive inhibitors of CYP3A4, on the
pharmacokinetics of repaglinide has been studied in healthy subjects. Co-administration of 200 mg
ketoconazole increased the repaglinide (AUC and Cmax) by 1.2-fold with profiles of blood glucose
concentrations altered by less than 8% when administered concomitantly (a single dose of 4 mg
repaglinide). Co-administration of 100 mg itraconazole, an inhibitor of CYP3A4, has also been
studied in healthy volunteers, and increased the AUC by 1.4-fold. No significant effect on the glucose
level in healthy volunteers was observed. In an interaction study in healthy volunteers, co-
administration of 250 mg clarithromycin, a potent mechanism-based inhibitor of CYP3A4, slightly
increased the repaglinide (AUC) by 1.4-fold and Cmax by 1.7-fold and increased the mean incremental
AUC of serum insulin by 1.5-fold and the maximum concentration by 1.6-fold. The exact mechanism
of this interaction is not clear.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) glucose (HOS-088412) itraconazole (HOS-084516) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2018-05-14T02:00:00Z · SHA-256 4c973e31eb747a16f464340bcfe327b4eb470ef0597a3a9d0a9fc8e0d35f01d0 · Passage 87f43c80efc4087eb3a239c087cbe51c7443c8eec3071c799c234a855ad41389 · Zeichen 3893–4892 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 17
HOS-108895 · Präparat HOS-093083
Due to induction of lamotrigine In patients starting or stopping
glucuronidation Kaletra while currently taking
maintenance dose of lamotrigine:
Valproate: ↓ lamotrigine dose may need to be
increased if Kaletra is added, or
decreased if Kaletra is
discontinued; therefore plasma
lamotrigine monitoring should be
conducted, particularly before and
during 2 weeks after starting or
stopping Kaletra, in order to see if
lamotrigine dose adjustment is
needed.
In patients currently taking Kaletra
and starting lamotrigine: no dose
adjustments to the recommended
dose escalation of lamotrigine
should be necessary.
Antidepressants and Anxiolytics
Trazodone single dose Trazodone: It is unknown whether the
AUC: ↑ 2.4-fold combination of Kaletra causes a
(Ritonavir, 200 mg BID) similar increase in trazodone
Adverse events of nausea, exposure. The combination should
dizziness, hypotension and be used with caution and a lower
syncope were observed following dose of trazodone should be
co-administration of trazodone considered.
and ritonavir.
Antifungals
Ketoconazole and Ketoconazole, Itraconazole: High doses of ketoconazole and
Itraconazole Serum concentrations may be itraconazole (> 200 mg/day) are
increased due to CYP3A not recommended.
inhibition by lopinavir/ritonavir.
Voriconazole Voriconazole: Co-administration of voriconazole
Concentrations may be decreased. and low dose ritonavir (100 mg
BID) as contained in Kaletra
should be avoided unless an
assessment of the benefit/risk to
patient justifies the use of
voriconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) valproate (HOS-085955) ketoconazole (HOS-084513) voriconazole (HOS-084524) itraconazole (HOS-084516) trazodone (HOS-086251)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage cc67e2cdf7b4bd67992a77fee82c028a01ca61b900711d375f1043368d2697bb · Zeichen 27086–30540 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53
HOS-109012 · Präparat HOS-093083
Due to induction of lamotrigine In patients starting or stopping
glucuronidation Kaletra while currently taking
maintenance dose of lamotrigine:
Valproate: ↓ lamotrigine dose may need to be
increased if Kaletra is added, or
decreased if Kaletra is discontinued;
therefore plasma lamotrigine
monitoring should be conducted,
particularly before and during 2
weeks after starting or stopping
Kaletra, in order to see if lamotrigine
dose adjustment is needed.
In patients currently taking Kaletra
and starting lamotrigine: no dose
adjustments to the recommended
dose escalation of lamotrigine should
be necessary.
Antidepressants and Anxiolytics
Trazodone single dose Trazodone: It is unknown whether the
AUC: ↑ 2.4-fold combination of Kaletra causes a
(Ritonavir, 200 mg similar increase in trazodone
BID) Adverse events of nausea, exposure. The combination should
dizziness, hypotension and be used with caution and a lower dose
syncope were observed following of trazodone should be considered.
co-administration of trazodone
and ritonavir.
Antifungals
Ketoconazole and Ketoconazole, Itraconazole: High doses of ketoconazole and
Itraconazole Serum concentrations may be itraconazole (> 200 mg/day) are not
increased due to CYP3A recommended.
inhibition by lopinavir/ritonavir.
Voriconazole Voriconazole: Co-administration of voriconazole
Concentrations may be decreased. and low dose ritonavir (100 mg BID)
as contained in Kaletra should be
avoided unless an assessment of the
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) valproate (HOS-085955) ketoconazole (HOS-084513) voriconazole (HOS-084524) itraconazole (HOS-084516) trazodone (HOS-086251)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage b7549f913c063162484a547a54d17aa41fc44fb9504b9f1472817c41a1f18572 · Zeichen 26672–29701 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 89
HOS-109088 · Präparat HOS-093083
Antidepressants and Anxiolytics
Trazodone single dose Trazodone: It is unknown whether the
AUC: ↑ 2.4-fold combination of Kaletra causes a
(Ritonavir, 200 mg similar increase in trazodone
BID) Adverse events of nausea, exposure. The combination should
dizziness, hypotension and be used with caution and a lower
syncope were observed following dose of trazodone should be
co-administration of trazodone considered.
and ritonavir.
Antifungals
Ketoconazole and Ketoconazole, Itraconazole: High doses of ketoconazole and
Itraconazole Serum concentrations may be itraconazole (> 200 mg/day) are not
increased due to CYP3A recommended.
inhibition by lopinavir/ritonavir.
Voriconazole Voriconazole: Co-administration of voriconazole
Concentrations may be decreased. and low dose ritonavir (100 mg
BID) as contained in Kaletra should
be avoided unless an assessment of
the benefit/risk to patient justifies
the use of voriconazole.
Anti-gout agents:
Colchicine single dose Colchicine: Concomitant administration of
AUC: ↑ 3-fold Kaletra with colchicine in patients
(Ritonavir 200 mg twice Cmax: ↑ 1.8-fold with renal and/or hepatic
daily) Due to P-gp and/or CYP3A4 impairment is contraindicated due
inhibition by ritonavir. to a potential increase of colchicine-
related serious and/or
life-threatening reactions such as
neuromuscular toxicity (including
rhabdomyolysis) (see sections 4.3
and 4.4). A reduction in colchicine
dosage or an interruption of
colchicine treatment is
recommended in patients with
normal renal or hepatic function if
treatment with Kaletra is required.
Refer to colchicine prescribing
information.
Antihistamines
Astemizole Serum concentrations may be Concomitant administration of
Terfenadine increased due to CYP3A Kaletra and astemizole and
inhibition by lopinavir/ritonavir. terfenadine is contraindicated as it
may increase the risk of serious
arrhythmias from these agents (see
section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) voriconazole (HOS-084524) itraconazole (HOS-084516) trazodone (HOS-086251) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 9043d84be2324d7e08bc16eeeba0c8c1136fbb4075d51aeb08ee163e186d9cab · Zeichen 28361–32171 im Abschnitt
Wechselwirkungen · Protopic
Protopic 0.03% ointment · Abschnitt 4.5 · PDF-Seite 5
HOS-109232 · Präparat HOS-093151
Systemically available tacrolimus is metabolised via the hepatic Cytochrome P450 3A4 (CYP3A4).
Systemic exposure from topical application of tacrolimus ointment is low (<1.0 ng/ml) and is unlikely
to be affected by concomitant use of substances known to be inhibitors of CYP3A4. However, the
possibility of interactions cannot be ruled out and the concomitant systemic administration of known
CYP3A4 inhibitors (e.g. erythromycin, itraconazole, ketoconazole and diltiazem) in patients with
widespread and/or erythrodermic disease should be done with caution.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) ketoconazole (HOS-084513) itraconazole (HOS-084516) erythromycin (HOS-084514)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-03T12:15:00Z · SHA-256 5825006b3b9f5f6765fd606bf2f8808250e5df6121179a915de3a36fc9e9b9e4 · Passage 8a824b296c7b74170b7137e2fa5b4579f58193231aaeb951239988c5b7be0106 · Zeichen 253–811 im Abschnitt
Wechselwirkungen · Protopic
Protopic 0.1% ointment · Abschnitt 4.5 · PDF-Seite 17
HOS-109246 · Präparat HOS-093151
Systemically available tacrolimus is metabolised via the hepatic Cytochrome P450 3A4 (CYP3A4).
Systemic exposure from topical application of tacrolimus ointment is low (< 1.0 ng/ml) and is unlikely
to be affected by concomitant use of substances known to be inhibitors of CYP3A4. However, the
possibility of interactions cannot be ruled out and the concomitant systemic administration of known
CYP3A4 inhibitors (e.g. erythromycin, itraconazole, ketoconazole and diltiazem) in patients with
widespread and/or erythrodermic disease should be done with caution.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) ketoconazole (HOS-084513) itraconazole (HOS-084516) erythromycin (HOS-084514)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-03T12:15:00Z · SHA-256 5825006b3b9f5f6765fd606bf2f8808250e5df6121179a915de3a36fc9e9b9e4 · Passage 3484056429fcfa04e5e69d58fac15375732ed184c20de1fe109b7c1574fe203c · Zeichen 253–812 im Abschnitt
Wechselwirkungen · Cancidas (previously Caspofungin MSD)
CANCIDAS 50 mg powder for concentrate for solution for infusion CANCIDAS 70 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 5
HOS-109311 · Präparat HOS-093179
Clinical studies in healthy adult volunteers show that the pharmacokinetics of caspofungin are not
altered to a clinically relevant extent by itraconazole, amphotericin B, mycophenolate, nelfinavir, or
tacrolimus. Caspofungin did not influence the pharmacokinetics of amphotericin B, itraconazole,
rifampicin or mycophenolate mofetil. Although safety data are limited it appears that no special
precautions are needed when amphotericin B, itraconazole, nelfinavir or mycophenolate mofetil are
co-administered with caspofungin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nelfinavir (HOS-084520) caspofungin (HOS-109306) amphotericin B (HOS-109312) itraconazole (HOS-084516) tacrolimus (HOS-085202) mycophenolate (HOS-085189) mycophenolate mofetil (HOS-085154)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-08T16:40:00Z · SHA-256 6dd11a424b362e655ce61e4c49586bb6e658af1133d504982e2602258f5f83f7 · Passage 13b361f5c82bacf40bdc68a7213cf3819b3cc95386c90e34a014dd9a2eb79937 · Zeichen 1570–2096 im Abschnitt
Wechselwirkungen · Tracleer
Tracleer 62.5 mg film-coated tablets Tracleer 125 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-109922 · Präparat HOS-093279
Fluconazole and other inhibitors of both CYP2C9 and CYP3A4: Co-administration with fluconazole,
which inhibits mainly CYP2C9, but to some extent also CYP3A4, could lead to large increases in
plasma concentrations of bosentan. The combination is not recommended. For the same reason,
concomitant administration of both a potent CYP3A4 inhibitor (such as ketoconazole, itraconazole or
ritonavir) and a CYP2C9 inhibitor (such as voriconazole) with Tracleer is not recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) voriconazole (HOS-084524) lead (HOS-085592) itraconazole (HOS-084516) fluconazole (HOS-087945) ritonavir (HOS-084521) bosentan (HOS-086291)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-25T15:01:00Z · SHA-256 eddfcd40df26bd01c2c7847da53c544c94e0bafb8bcc62374b5c7788669470bc · Passage f0f8a00a013cf8d3c79a39ec409d4ac945f15268559ebbcad8f852840ca7a673 · Zeichen 851–1324 im Abschnitt
Wechselwirkungen · Tracleer
Tracleer 62.5 mg film-coated tablets Tracleer 125 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-109936 · Präparat HOS-093279
Ketoconazole: Co-administration for 6 days of bosentan 62.5 mg twice daily with ketoconazole, a
potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan approximately 2-fold. No
dose adjustment of Tracleer is considered necessary. Although not demonstrated through in vivo
studies, similar increases in bosentan plasma concentrations are expected with the other potent
CYP3A4 inhibitors (such as itraconazole or ritonavir). However, when combined with a CYP3A4
inhibitor, patients who are poor metabolisers of CYP2C9 are at risk of increases in bosentan plasma
concentrations that may be of higher magnitude, thus leading to potential harmful adverse events.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) itraconazole (HOS-084516) ritonavir (HOS-084521) bosentan (HOS-086291)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-25T15:01:00Z · SHA-256 eddfcd40df26bd01c2c7847da53c544c94e0bafb8bcc62374b5c7788669470bc · Passage 952d7c2c68ef8030b7abcf275fd2bcf42069f7e4a3bd6fa57570b72d26500dbe · Zeichen 7461–8135 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.